Reverse-phase protein microarrays: Application to biomarker discovery and translational medicine

Expert Review of Molecular Diagnostics

Volumn 7, Issue 5, 2007, Pages 625-633

  VanMeter, Amy ^a   Signore, Michele ^a,b   Pierobon, Mariaelena ^a,c   Espina, Virginia ^a   Liotta, Lance A ^a   Petricoin III, Emanuel F ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Biomarker; Individualized therapy; Microarray; Phosphoprotein; Protein; Reverse phase protein microarray; Translational medicine

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAPECITABINE; CELL PROTEIN; DOCETAXEL; ERLOTINIB; PD 176252; PD176252; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ASPIRATION BIOPSY; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; LASER CAPTURE MICRODISSECTION; MEDICAL RESEARCH; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; BIOPSY; GENETICS; GENOMICS; METHODOLOGY; NEOPLASM; PATHOLOGY; PROTEOMICS;

BIOLOGICAL MARKERS; BIOPSY; GENOMICS; HUMANS; NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS;

EID: 35148839816     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.5.625     Document Type: Review

References (62)

1. Liotta LA, Espina V, Mehta AI et al. Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell 3(4), 317-325 (2003). •• In-depth discussion and explanation of microarray formats, including limitations and applications.
2. Petricoin E, Wulfkuhle J, Espina V, Liotta LA. Clinical proteomics revolutionizing disease detection and patient tailoring therapy. J. Proteome Res. 3(2), 209-217 (2004).
3. Petricoin EF, Liotta LA. Proteomic approaches in cancer risk and response assessment. Trends Mol. Med. 10(2), 59-64 (2004).
4. Petricoin EF, Bichsel V, Calvert V et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J. Clin. Oncol. 23(15), 3614-3621 (2005).
5. Petricoin EF III, Espina V, Araujo RP et al. Phosphoprotein pathway mapping: akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 67(7), 3431-3440 (2007). •• Current comprehensive description of the clinical utility of reverse-phase protein microarrays.
6. Chan SM, Ermann J, Su L, Fathman CG, Utz PJ. Protein microarrays for multiplex analysis of signal transduction pathways. Nat. Med. 10(12), 1390-1396 (2004).
7. Meric-Bernstam F, Mills GB. Mammalian target of rapamycin. Semin. Oncol. 31(6 Suppl. 16), 10-17; discussion 33 (2004).
8. Schmelzle K, White FM. Phosphoproteomics approaches to elucidate cellular signaling networks. Curr. Opin. Biotechnol. 17(4), 406-414 (2006). • Current review of phosphoproteomic technologies for molecular profiling of cell signaling kinases.
9. Emmert-Buck MR, Bonner RF, Smith PD et al. Laser capture microdissection. Science 274(5289), 998-1001 (1996).
10. Bonner RF, Emmert-Buck M, Cole K et al. Laser capture microdissection: molecular analysis of tissue. Science 278(5342), 1481-1483 (1997).
11. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276(5311), 404-407 (1997).
12. Liotta LA, Kohn EC. Stromal therapy the next step in ovarian cancer treatment. J. Natl Cancer Inst. 94(15), 1113-1114 (2002).
13. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 411(6835), 375-379 (2001).
14. Haab BB. Antibody arrays in cancer research. Mol. Cell. Proteomics 4(4), 377-383 (2005). • Current review of antibody arrays.
15. Lal SP, Christopherson RI, dos Remedios CG. Antibody arrays: an embryonic but rapidly growing technology. Drug Discov. Today 7(18 Suppl.), S143-S149 (2002).
16. Steinitz M, Tamir S. An improved method to create nitrocellulose particles suitable for the immobilization of antigen and antibody. J. Immunol. Methods 187(1), 171-177 (1995).
17. Knickerbocker T, Chen JR, Thadhani R, MacBeath G. An integrated approach to prognosis using protein microarrays and nonparametric methods. Mol. Syst. Biol. 3, 123 (2007).
18. Kusnezow W, Syagailo YV, Ruffer S et al. Optimal design of microarray immunoassays to compensate for kinetic limitations: theory and experiment. Mol. Cell. Proteomics 5(9), 1681-1696 (2006).
19. Templin MF, Stoll D, Schrenk M et al. Protein microarray technology. Trends Biotechnol. 20(4), 160-166 (2002).
20. Zhu H, Snyder M. Protein chip technology Curr. Opin. Chem. Biol. 7(1), 55-63 (2003).
21. Miller JC, Zhou H, Kwekel J et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3(1), 56-63 (2003).
22. Knezevic V, Leethanakul C, Bichsel VE et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 1(10), 1271-1278 (2001).
23. Paweletz CP, Charboneau L, Bichsel VE et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20(16), 1981-1989 (2001). • Seminal paper describing reverse-phase protein microarray technology, linearity, reproducibility and sensitivity
24. Hultschig C, Kreutzberger J, Seitz H et al. Recent advances of protein microarrays. Curr. Opin. Chem. Biol. 10(1), 4-10 (2006).
25. Song S, Li B, Wang L et al. A cancer protein microarray platform using antibody fragments and its clinical applications. Mol. Biosyst. 3(2), 151-158 (2007).
26. Wilson DS, Nock S. Recent developments in protein microarray technology. Angew. Chem. Int. Ed. Engl. 42(5), 494-500 (2003).
27. Haab BB. Applications of antibody array platforms. Curr. Opin. Biotechnol. 17(4), 415-421 (2006).
28. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 1(9), 683-695 (2002).
29. Charboneau L. Utility of reverse phase protein arrays: applications to signaling pathways and human body arrays. Brief. Funct. Genomic. Proteomic. 1(3), 305-315 (2002).
30. Belluco C, Mammano E, Petricoin E et al. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin. Chim. Acta 357(2), 180-183 (2005).
31. Gulmann C, Espina V, Petricoin E III et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin. Cancer Res. 11(16), 5847-5855 (2005).
32. Rapkiewicz A, Espina V, Zujewski JA et al. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer 111(3), 173-184 (2007).
33. Sheehan KM, Calvert VS, Kay EW et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell. Proteomics 4(4), 346-355 (2005).
34. Wulfkuhle JD, Aquino JA Calvert VS et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3(11), 2085-2090 (2003).
35. Ekins RP. Multi-analyte immunoassay. J. Pharm. Biomed. Anal. 7(2), 155-168 (1989). • Details the theory of analyte sensitivity in relation to spot size for immunassays.
36. Kusnezow W, Syagailo YV, Goychuk I, Hoheisel JD, Wild DG. Antibody microarrays: the crucial impact of mass transport on assay kinetics and sensitivity. Expert Rev. Mol. Diagn. 6(1), 111-124 (2006).
37. Kusnezow W, Syagailo YV, Ruffer S et al. Kinetics of antigen binding to antibody microspots: strong limitation by mass transport to the surface. Proteomics 6(3), 794-803 (2006).
38. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J. Immunol. Methods 125(1-2), 279-285 (1989).
39. Bobrow MN, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. J. Immunol. Methods 137(1), 103-112 (1991). • Description of signal amplification technology that is applicable to reverse-phase protein microarrays.
40. Hunyady B, Krempels K, Harta G, Mezey E. Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J. Histochem. Cytochem. 44(12), 1353-1362 (1996).
41. King G, Payne S, Walker F, Murray GI. A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J. Pathol. 183(2), 237-241 (1997).
42. Tibes R, Qiu Y, Lu Y et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5(10), 2512-2521 (2006). • Good example of reverse-phase assay (RPA) technology applied to peripheral blood samples.
43. Miller LD, Long PM, Wong L et al. Optimal gene expression analysis by microarrays. Cancer Cell 2(5), 353-361 (2002).
44. Seong SY. Microimmunoassay using a protein chip: optimizing conditions for protein immobilization. Clin. Diagn. Lab. Immunol. 9(4), 927-930 (2002).
45. Tonkinson JL, Stillman BA. Nitrocellulose: a tried and true polymer finds utility as a post-genomic substrate. Front Biosci. 7, C1-C12 (2002).
46. Nijdam AJ, Ming-Cheng Cheng M, Geho DH et al. Physicochemically modified silicon as a substrate for protein microarrays. Biomaterials 28(3), 550-558 (2007).
47. Espina V, Geho D, Mehta AI et al. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest. 23(1), 36-46 (2005).
48. Grubb RL, Calvert VS, Wulkuhle JD et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3(11), 2142-2146 (2003).
49. Iyengar P, Espina V, Williams TW et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J. Clin. Invest. 115(5), 1163-1176 (2005). • Interesting and comprehensive study detailing tumor microenvironment effects using several analytical techniques, including laser capture microdissection and RPA.
50. Paweletz CP, Trock B, PennanenM et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers 17(4), 301-307 (2001).
51. Menard C, Susil RC, Choyke P et al. An interventional magnetic resonance imagingtechnique for the molecular characterization of intraprostatic dynamic contrast enhancement. Mol. Imaging 4(1), 63-66 (2005).
52. Becker KF, Schott C, Hipp S et al. Quantitative protein analysis from formalin-fixed tissues implications for translational clinical research and nanoscale molecular diagnosis. J. Pathol. 211(3), 370-378 (2007).
53. Fan YH, Hu Z, Li C et al. In vitro expression levels of cell-cycle checkpoint proteins are assodated with cellular DNA repair capacity in peripheral blood lymphocytes a multivariate analysis. J. Proteome Res. 6(4), 1560-1567 (2007).
54. Shankavaram UT, Reinhold WC, Nishizuka S et al. Transcript and portein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol. Cancer Ther. 6(3), 820-832 (2007). • High-throughput molecular profiling of the NCI-60 cell lines
55. Machida K, Thompson CM, Dierck K et al. High-throughput phosphotyrosine profiling using SH2 domains. Mol. Cell 26(6), 899-915 (2007). • Another example of high-throughput molecular profiling using reverse-phase protein microarrays.
56. Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439(7073), 168-174 (2006).
57. Yokoyama T, Kondo Y, Kondo S. Roles of mTOR and STAT3 in autophagy induced by telomere 3′ overhang-specific DNA oligonucleotides. Autophagy 3(5), 496-498 (2007).
58. Aoki H, Iwado E, Eller MS et al. Telomere 3′ overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J. (2007) (Epub ahead of print).
59. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA 286(18), 2211-2214 (2001).
60. Zhang Q, Bhola NE, Lui VW et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol. Cancer Ther. 6(4), 1414-1424 (2007).
61. Major SM, Nishizuka S, Morita D et al. AbMiner: a bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies. BMC Bioinformatics 7, 192 (2006).
62. Huang D, Casale GP, Tian J et al. Quantitative fluorescence imaging analysis for cancer biomarker discovery application to beta-catenin in archived prostate specimens. Cancer Epidemiol. Biomarkers Prev. 16(7), 1371-1381 (2007).